



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Mary Collins et al.

Serial No.: 09/805,801

Filed: March 13, 2001

For: *Use of a Combination of Agents that Modulate
B7 Activity in Inhibiting Intestinal Allograft Rejection*

Attorney Docket No.: GNN-016

Group Art Unit: 1614

Examiner:

RECEIVED
APR 25 2002
TECH CENTER 1600/2900

RECEIVED
APR 25 2002
TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231


Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

April 19, 2002

Date of Signature and of Mail Deposit

By:


Megan E. Williams, Esq
Registration No. 43,270
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT


Dear Sir:

Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 C.F.R. §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


Megan E. Williams, Esq
Registration No. 43,270
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: April 19, 2002

AEM/MEW/SYH/ipc
Enclosures



LAHIVE
&
COCKFIELD
LLP

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
RALPH A. LOREN
GIULIO A. DeCONTI, JR.
ANN LAMPORT HAMMITTE
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
PETER C. LAURO
JEANNE M. DIGIORGIO
DEBRA J. MILASINCIC, Ph.D.
DAVID J. RIKKERS
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER

1614

CYNTHIA L. KANIK, Ph.D.
MEGAN E. WILLIAMS, Ph.D.
RICHANAND
MICHAEL PHILLIPPS *
LISA M. DIROCCO
HATHAWAY P. RUSSELL **
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.
PETER A. DIMATTIA
VINCENT P. LOCCISANO
MERIDETH C. ARNOLD

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT

1644

PATENT AGENTS
THEODORE R. WEST
SHAYNE Y. HUFF, Ph.D.
DANIEL B. KO

TECHNICAL SPECIALISTS
CYNTHIA M. SOROCOS
PETER W. DINI, Ph.D.
EUIHOON LEE
JENNIFER K. ROSENFELD
ALLAN TAMESHTIT, Ph.D.
CATHERINE E. McPHERSON
ERIC F. WAGNER, Ph.D.
SHAHID HASAN, Ph.D.
JACOB G. WEINTRAUB
JONATHAN M. SPARKS, Ph.D.
CRISTIN E. HOWLEY, Ph.D.

* Admitted in NY only
** Admitted in TX only

APR 25 2002

RECEIVED

April 19, 2002

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Patent Application No.: 09/805,801
For: *Use of a Combination of Agents that Modulate B7 Activity
in Inhibiting Intestinal Allograft Rejection*
Inventor: Mary Collins et al.
Filed: March 13, 2001
Our Ref. No.: GNN-016

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Information Disclosure Statement;
2. PTO Form 1449;
3. Copies of references cited in PTO Form 1449 (28); and
4. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.


I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

April 19, 2002

Date


Megan E. Williams, Esq. Reg. No. 43,270

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


Megan E. Williams, Esq.
Registration No. 43,270
Attorney for Applicants

p#5
RECEIVED
APR 25 2002
TECH CENTER 1600/2900